MEG3 targets miR-184 and Wnt/β-catenin and modulates properties of osteosarcoma

Area of Science:

• Molecular Biology
• Oncology
• RNA Biology

Background:

• Osteosarcoma (OS) exhibits abnormal expression of long non-coding RNA (lncRNA) MEG3 and microRNA-184 (miR-184).
• Understanding the regulatory relationship between MEG3 and miR-184 is crucial for OS treatment.

Purpose of the Study:

• To investigate the regulatory role of MEG3 on miR-184 and the WNT/β-catenin pathway in osteosarcoma.
• To evaluate the therapeutic potential of MEG3 in osteosarcoma progression.

Main Methods:

• Adenoviral vector-mediated MEG3 overexpression in OS cells.
• Assessment of proliferation, migration, and apoptosis in vitro.
• In vivo tumor growth restriction studies.
• Reversal experiments using miR-184 mimic.

Main Results:

• MEG3 negatively regulates miR-184 expression and downstream WNT/β-catenin pathway components (β-catenin, TCF4, c-MYC).
• MEG3 overexpression inhibits OS cell proliferation and migration, and promotes apoptosis in vitro.
• MEG3 restricts OS tumor growth in vivo.
• The effects of MEG3 were reversed by miR-184 mimic, indicating a cooperative regulatory mechanism.

Conclusions:

• MEG3 acts as a tumor suppressor in osteosarcoma by inhibiting miR-184 and the WNT/β-catenin pathway.
• MEG3 and miR-184 cooperatively regulate osteosarcoma cell proliferation, migration, and apoptosis.
• MEG3 holds potential as a therapeutic agent for osteosarcoma.